Epidemiological Aspects, Clinical Features and Treatment Outcome in Children Suffering Hepatoblastoma
Iranian Journal of Pediatric Surgery,
Vol. 7 No. 1 (2021),
27 April 2021
,
Page 1-8
https://doi.org/10.22037/irjps.v7i1.33635
Abstract
Introduction: Hepatoblastoma (HBL) is the most common primary liver tumor within childhood. Entire tumor resection is basis for ultimate cure for HBL and supports the only pleasant chance of long-standing disease-free survival.
Objectives: In the current survey, we attempted to evaluate the long-term survival of children with HBL with surgical resection in a referral children hospital in Iran within the last decade.
Materials and Methods:This retrospective descriptive study was conducted on all children who suffered HBL and undergone surgery between 2006 and 2016. Reviewing the recorded hospital files led to a sample of 30 eligible patients. The baseline characteristics of the patients were all collected by reviewing the files.
Results:In total, 30 consecutive children (21 male and 9 female) suffering HBL were described. Of those, 40.0% aged less than 12 months and only 6.7% aged higher than 36 months. The most common clinical manifestations were asymptomatic abdominal mass (in 66.7%) followed by fever (in 10.0%) and pain (in 10.0%). In more than half of the patients (53.3%), right lobe involved, while left lobe involved in 16.7%. based on histologicalreport,marginal involvement was found in 75.0% of children, margin intact in 15.0% and margin free feature in 5.0%. Forty percent of children suffered from epithelial subtype of tumor, 20.0% from mixed epithelial and mesenchymal subtypes, and 13.3% from embryonal pattern. In total, 63.3% were scheduled for complete surgical resection followed by chemotherapy. Postoperatively, 40.0% of children remained free of complications, whereas postoperative bleeding occurred in 20.0% and biloma in 40.0%. Overall, 76.9% of patients were completely cured, 7.7% suffered from pulmonary metastasis and 3.9% required liver transplantation. Postoperative death occurred in 11.5%.
Conclusions: Considering surgical resection followed by chemotherapy leads to high cure rate, however a notable number of affected children suffer postoperative complication, requiring liver transplantation, pulmonary metastasis, or even non-survived emphasizing a serious review of the treatment protocols.
- Hepatoblastoma
- Children
- Liver tumor
How to Cite
References
Hiyama E:Pediatric hepatoblastoma: diagnosis and treatment.TranslPediatr 2014;3(4):293-9.
Czauderna P, Garnier H:Hepatoblastoma: current understanding, recent advances, and controversies. F1000Res 2018;7:53.
Spector LG, Birch J: The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59(5):776-9.
Schnater JM, Köhler SE, Lamers WH, et al: Where do we stand with hepatoblastoma? A review. Cancer 2003; 98(4):668-78.
Meyers RL, Maibach R, Hiyama E, et al:Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol2017;18(1):122-131.
Sharma D, Subbarao G, Saxena R:Hepatoblastoma. SeminDiagnPathol 2017;34(2):192-200.
O'Neill AF, Towbin AJ, Krailo MD, et al: Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. J ClinOncol 2017;35(30):3465-3473.
Chavhan GB, Mann E, Kamath BM, et al: Gadobenate-dimeglumine-enhanced magnetic resonance imaging for hepatic lesions in children. PediatrRadiol 2014;44(10):1266-74.
Kremer N, Walther AE, Tiao GM: Management of hepatoblastoma: an update. CurrOpinPediatr 2014;26(3):362-9.
Czauderna P, Haeberle B, Hiyama E, et al: The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 2016;52:92-101.
Meyers RL, Maibach R, Hiyama E, et al:Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol 2017; 18(1):122-131.
Busweiler LA, Wijnen MH, Wilde JC, et al: Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). PediatrSurgInt 2017;33(1):23-31.
Czauderna P1, Lopez-Terrada D, Hiyama E, et al:Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. CurrOpinPediatr 2014;26(1):19-28.
Musick SR, Smith M, Rouster AS, et al:Hepatoblastoma. StatPearls [Internet] 2020 Nov 19.
Roebuck DJ, Aronson D, Clapuyt P, et al: International Childhood LiverTumor Strategy Group.2005 PRETEXT:a revised staging system for primary malignant livertumours of childhood developed by the SIOPEL group. PediatrRadiol 2007;37(2):123-32; quiz 249-50.
Ortega JA, Krailo MD, Haas JE, et al:Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children’s Cancer Study Group. J ClinOncol 1991;9:2167-2176.
Douglass EC, Reynolds M, Finegold M, et al:Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group Study. J ClinOncol 1993;11:96-99.
Ortega JA, Douglass EC, Feusner JH, et al: Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J ClinOncol2000;18:2665-2675.
Ammann RA, Plaschkes J, Leibundgut K: Congenital hepatoblastoma: a distinct entity? Med PediatrOncol1999;32:466-468.
Stocker JT:Hepatoblastoma. SeminDiagnPathol. 1994;11:136-143.
Haas JE, Muczynski KA, Krailo M, et al:Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989;64:1082-1095.
Stringer MD, Hennayake S, Howard ER, et al: Improved outcome for children with hepatoblastoma. Br J Surg 1995;82:386-391.
Seo T, Ando H, Watanabe Y, et al:Treatment of hepatoblastoma: less extensive hepatectomy after effective preoperative chemotherapy with cisplatin and Adriamycin. Surgery 1998;123:407-414.
Black CT, Luck SR, Musemeche CA, et al: Aggressive excision of pulmonary metastases is warranted in the management of childhood hepatic tumors. J PediatrSurg1991;26:1082-1086.
- Abstract Viewed: 254 times
- PDF Downloaded: 286 times